Aytu BioPharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
Aytu BioPharma has a total shareholder equity of $27.7M and total debt of $15.1M, which brings its debt-to-equity ratio to 54.6%. Its total assets and total liabilities are $118.1M and $90.4M respectively.
Belangrijke informatie
54.6%
Verhouding schuld/eigen vermogen
US$15.13m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$20.01m |
| Aandelen | US$27.72m |
| Totaal verplichtingen | US$90.38m |
| Totaal activa | US$118.10m |
Recente financiële gezondheidsupdates
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Nov 01
Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Jun 14Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Recent updates
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly?
Nov 01It's Probably Less Likely That Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Will See A Huge Pay Rise This Year
Jun 20Here's Why Aytu BioPharma (NASDAQ:AYTU) Has A Meaningful Debt Burden
Jun 14US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation
Feb 14Analyse van de financiële positie
Kortlopende schulden: AYTU's short term assets ($61.9M) do not cover its short term liabilities ($62.2M).
Langlopende schulden: AYTU's short term assets ($61.9M) exceed its long term liabilities ($28.2M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: AYTU has more cash than its total debt.
Schuld verminderen: AYTU's debt to equity ratio has increased from 0% to 54.6% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: AYTU has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: AYTU has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 11.7% each year